DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)

Information source: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cytomegalovirus Retinitis; HIV Infections

Intervention: Foscarnet sodium (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Astra USA

Official(s) and/or principal investigator(s):
Wool GM, Study Chair


To assess the relative efficacy of oral versus intravenous hydration during foscarnet sodium (Foscavir) induction therapy, as determined by changes in creatinine clearance. To estimate the timing and volume of oral fluid hydration required to establish a diuresis before and during intravenous Foscavir therapy. To assess the general tolerance of two hydration regimens by the adverse event profile associated with each.

Clinical Details

Official title: A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)

Study design: Primary Purpose: Treatment

Detailed description: Patients are randomized to receive oral hydration versus intravenous hydration therapy during concomitant intermittent intravenous Foscavir therapy for treatment of cytomegalovirus (CMV) retinitis. Treatment continues during 2 or 3 weeks of induction Foscavir therapy.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria Patients must have:

- Documented HIV infection.

- Recent diagnosis of CMV retinitis, by ophthalmoscopic appearance, that requires

induction therapy.

- No corneal, lens, or vitreous opacification that precludes examination of the fundi.

- No evidence of other end organ CMV infection.

- No evidence of tuberculous, diabetic, or hypertensive retinopathy.

Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded:

- Clinically significant cardiac, pulmonary, neurologic, gastrointestinal or renal

impairment that would prevent adequate voluntary oral hydration (e. g., intubation, coma, status post-gastrectomy, colon resection, gastrointestinal tumors, malabsorption, chronic diarrhea) OR with which hydration would be hazardous (e. g., congestive heart failure).

- Known allergy to foscarnet or related compounds.

- Considered noncompliant or unreliable for study participation.

Concurrent Medication: Excluded:

- Any investigational drug.

- Potentially nephrotoxic drugs (e. g., amphotericin B, aminoglycosides, cisplatin).

Prior Medication: Excluded:

- Any investigational drug within 28 days prior to study entry.

- Potentially nephrotoxic drugs (e. g., amphotericin B, aminoglycosides, cisplatin)

within 7 days prior to study entry.

Locations and Contacts

Dr Ralph Hansen, Beverly Hills, California 90210, United States

Dr G Michael Wool, Los Angeles, California 90067, United States

Dr Milan Fiala, Los Angeles, California 900246970, United States

AIDS Community Research Consortium, Redwood City, California 94063, United States

Ingenix Kern McNeill Decatur, Atlanta, Georgia 30309, United States

Dr John Karedes, Indianapolis, Indiana 46204, United States

Dr Paul Benson, Berkley, Michigan 48072, United States

Dr Ronald Nahass, Somerville, New Jersey 08876, United States

Dr Ronald J Grossman, New York, New York 10016, United States

Community Health Network, Rochester, New York 14620, United States

Austin Infectious Disease Consultants, Austin, Texas 78705, United States

Additional Information

Last updated: June 23, 2005

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017